2016
DOI: 10.1097/coc.0000000000000106
|View full text |Cite
|
Sign up to set email alerts
|

Primary Cardiac Sarcoma

Abstract: Cardiac sarcoma is a lethal tumor with an EMS of 25 months. The tumor histology could be a possible predictor of better survival. Although selection bias may have been present, multimodality therapy (surgery, radiation therapy, and chemotherapy) was associated with improved survival.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
53
1
5

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 97 publications
(69 citation statements)
references
References 49 publications
0
53
1
5
Order By: Relevance
“…Benign tumors such as fibroma, lipoma, hemangioma, and papillary fibroelastoma always have favorable prognosis after surgery operation. Sarcoma, which is a malignant neoplasm, is rarely seen and usually has a poor prognosis [11]. In a previous study, only 31.9% of patients with sarcoma underwent effective surgical resection because of advanced-stage tumors, metastatic extracardiac malignancy, and high comorbidity burdens [12].…”
Section: Discussionmentioning
confidence: 99%
“…Benign tumors such as fibroma, lipoma, hemangioma, and papillary fibroelastoma always have favorable prognosis after surgery operation. Sarcoma, which is a malignant neoplasm, is rarely seen and usually has a poor prognosis [11]. In a previous study, only 31.9% of patients with sarcoma underwent effective surgical resection because of advanced-stage tumors, metastatic extracardiac malignancy, and high comorbidity burdens [12].…”
Section: Discussionmentioning
confidence: 99%
“…Patients who receive multimodality treatment options (combination of surgery, radiation therapy, and chemotherapy) have improved survival compared to patients treated with only one modality. Even with all these strategies, longest survival remained less than 3 years [ 7 ]. Cardiac transplantation is not currently recommended due to poor survival benefit in few studies [ 8 ], except for very selected group of patients with subsequent immunotherapy [ 9 ].…”
Section: Discussionmentioning
confidence: 99%
“…Local control is important in this disease to improve these symptoms and prevent development of metastatic disease ( 3 ). However, in general, survival is poor with median survival between 12 and 36 months with multi-modality therapy ( 4 , 5 ).…”
Section: Discussionmentioning
confidence: 99%